Literature DB >> 23019498

Clinically employed opioid analgesics produce antinociception via μ-δ opioid receptor heteromers in Rhesus monkeys.

Ajay S Yekkirala1, Matthew L Banks, Mary M Lunzer, Stevens S Negus, Kenner C Rice, Philip S Portoghese.   

Abstract

Morphine and related drugs are widely employed as analgesics despite the side effects associated with their use. Although morphine is thought to mediate analgesia through mu opioid receptors, delta opioid receptors have been implicated in mediating some side effects such as tolerance and dependence. Here we present evidence in rhesus monkeys that morphine, fentanyl, and possibly methadone selectively activate mu-delta heteromers to produce antinociception that is potently antagonized by the delta opioid receptor antagonist, naltrindole (NTI). Studies with HEK293 cells expressing mu-delta heteromeric opioid receptors exhibit a similar antagonism profile of receptor activation in the presence of NTI. In mice, morphine was potently inhibited by naltrindole when administered intrathecally, but not intracerebroventricularly, suggesting the possible involvement of mu-delta heteromers in the spinal cord of rodents. Taken together, these results strongly suggest that, in primates, mu-delta heteromers are allosterically coupled and mediate the antinociceptive effects of three clinically employed opioid analgesics that have been traditionally viewed as mu-selective. Given the known involvement of delta receptors in morphine tolerance and dependence, our results implicate mu-delta heteromers in mediating both antinociception and these side effects in primates. These results open the door for further investigation in humans.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23019498      PMCID: PMC3447399          DOI: 10.1021/cn300049m

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  40 in total

1.  Cloning of a delta opioid receptor by functional expression.

Authors:  C J Evans; D E Keith; H Morrison; K Magendzo; R H Edwards
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

2.  Opioid interactions in rhesus monkeys: effects of delta + mu and delta + kappa agonists on schedule-controlled responding and thermal nociception.

Authors:  Glenn W Stevenson; John E Folk; David C Linsenmayer; Kenner C Rice; S Stevens Negus
Journal:  J Pharmacol Exp Ther       Date:  2003-10-13       Impact factor: 4.030

3.  Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice.

Authors:  E E Abdelhamid; M Sultana; P S Portoghese; A E Takemori
Journal:  J Pharmacol Exp Ther       Date:  1991-07-01       Impact factor: 4.030

4.  Genetic dissociation of opiate tolerance and physical dependence in delta-opioid receptor-1 and preproenkephalin knock-out mice.

Authors:  Joshua F Nitsche; Alwin G P Schuller; Michael A King; Min Zengh; Gavril W Pasternak; John E Pintar
Journal:  J Neurosci       Date:  2002-12-15       Impact factor: 6.167

5.  Intrathecal substance P elicits a caudally-directed biting and scratching behavior in mice.

Authors:  J L Hylden; G L Wilcox
Journal:  Brain Res       Date:  1981-07-27       Impact factor: 3.252

6.  Naltrindole, a highly selective and potent non-peptide delta opioid receptor antagonist.

Authors:  P S Portoghese; M Sultana; A E Takemori
Journal:  Eur J Pharmacol       Date:  1988-01-27       Impact factor: 4.432

7.  Cloning and pharmacological characterization of a rat mu opioid receptor.

Authors:  R C Thompson; A Mansour; H Akil; S J Watson
Journal:  Neuron       Date:  1993-11       Impact factor: 17.173

8.  The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization.

Authors:  B L Kieffer; K Befort; C Gaveriaux-Ruff; C G Hirth
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

9.  Cloning and pharmacological characterization of a rat kappa opioid receptor.

Authors:  F Meng; G X Xie; R C Thompson; A Mansour; A Goldstein; S J Watson; H Akil
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

10.  Effects of opioid agonists selective for mu, kappa and delta opioid receptors on schedule-controlled responding in rhesus monkeys: antagonism by quadazocine.

Authors:  S S Negus; T F Burke; F Medzihradsky; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  1993-11       Impact factor: 4.030

View more
  19 in total

1.  Opioid activity of spinally selective analogues of N-naphthoyl-β-naltrexamine in HEK-293 cells and mice.

Authors:  Morgan Le Naour; Mary M Lunzer; Mike D Powers; Philip S Portoghese
Journal:  J Med Chem       Date:  2012-01-05       Impact factor: 7.446

2.  Opioid-galanin receptor heteromers mediate the dopaminergic effects of opioids.

Authors:  Ning-Sheng Cai; César Quiroz; Jordi Bonaventura; Alessandro Bonifazi; Thomas O Cole; Julia Purks; Amy S Billing; Ebonie Massey; Michael Wagner; Eric D Wish; Xavier Guitart; William Rea; Sherry Lam; Estefanía Moreno; Verònica Casadó-Anguera; Aaron D Greenblatt; Arthur E Jacobson; Kenner C Rice; Vicent Casadó; Amy H Newman; John W Winkelman; Michael Michaelides; Eric Weintraub; Nora D Volkow; Annabelle M Belcher; Sergi Ferré
Journal:  J Clin Invest       Date:  2019-03-26       Impact factor: 14.808

3.  The opioid receptor triple agonist DPI-125 produces analgesia with less respiratory depression and reduced abuse liability.

Authors:  Shou-Pu Yi; Qing-Hong Kong; Yu-Lei Li; Chen-Ling Pan; Jie Yu; Ben-Qiang Cui; Ying-Fei Wang; Guan-Lin Wang; Pei-Lan Zhou; Li-Li Wang; Ze-Hui Gong; Rui-Bin Su; Yue-Hai Shen; Gang Yu; Kwen-Jen Chang
Journal:  Acta Pharmacol Sin       Date:  2017-05-15       Impact factor: 6.150

Review 4.  Novel GPCR paradigms at the μ-opioid receptor.

Authors:  G L Thompson; E Kelly; A Christopoulos; M Canals
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

Review 5.  Heteromers of μ-δ opioid receptors: new pharmacology and novel therapeutic possibilities.

Authors:  Wakako Fujita; Ivone Gomes; Lakshmi A Devi
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

6.  The bivalent ligand MCC22 potently attenuates hyperalgesia in a mouse model of cisplatin-evoked neuropathic pain without tolerance or reward.

Authors:  Giuseppe Cataldo; Samuel J Erb; Mary M Lunzer; Nhungoc Luong; Eyup Akgün; Philip S Portoghese; Julie K Olson; Donald A Simone
Journal:  Neuropharmacology       Date:  2019-04-07       Impact factor: 5.250

7.  In vitro and in vivo characterization of the bifunctional μ and δ opioid receptor ligand UFP-505.

Authors:  N Dietis; H Niwa; R Tose; J McDonald; V Ruggieri; M Filaferro; G Vitale; L Micheli; C Ghelardini; S Salvadori; G Calo; R Guerrini; D J Rowbotham; D G Lambert
Journal:  Br J Pharmacol       Date:  2018-05-14       Impact factor: 8.739

8.  Synthesis of Carfentanil Amide Opioids Using the Ugi Multicomponent Reaction.

Authors:  András Váradi; Travis C Palmer; Nathan Haselton; Daniel Afonin; Joan J Subrath; Valerie Le Rouzic; Amanda Hunkele; Gavril W Pasternak; Gina F Marrone; Attila Borics; Susruta Majumdar
Journal:  ACS Chem Neurosci       Date:  2015-07-21       Impact factor: 4.418

9.  Combination of a δ-opioid Receptor Agonist and Loperamide Produces Peripherally-mediated Analgesic Synergy in Mice.

Authors:  Daniel J Bruce; Cristina D Peterson; Kelley F Kitto; Eyup Akgün; Sophia Lazzaroni; Phillip S Portoghese; Carolyn A Fairbanks; George L Wilcox
Journal:  Anesthesiology       Date:  2019-09       Impact factor: 7.892

10.  An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans.

Authors:  Richard C Crist; Toni-Kim Clarke; Alfonso Ang; Lisa M Ambrose-Lanci; Falk W Lohoff; Andrew J Saxon; Walter Ling; Maureen P Hillhouse; R Douglas Bruce; George Woody; Wade H Berrettini
Journal:  Neuropsychopharmacology       Date:  2013-04-23       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.